Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:002907)

SHE:002907 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	774.69	764.14	680.84	774.72	837.23	876.09
Other Revenue	10.68	10.68	10.7	10.47	8.91	6.38
Revenue	785.37	774.82	691.54	785.18	846.14	882.47
Revenue Growth (YoY)	7.23%	12.04%	-11.93%	-7.20%	-4.12%	4.80%
Cost of Revenue	340.5	332.91	312.45	320.55	400.53	458.88
Gross Profit	444.87	441.91	379.1	464.63	445.61	423.59
Selling, General & Admin	309.16	308.36	263.88	292.53	297.82	269.07
Research & Development	58.79	59.13	78.12	58.82	41.72	36.48
Other Operating Expenses	14.71	10.65	9.39	12.34	11.58	9.82
Operating Expenses	383.17	379.55	349.7	367.04	350.65	314.47
Operating Income	61.69	62.36	29.4	97.59	94.95	109.13
Interest Expense	-0	-	-0.95	-14.42	-18.22	-17.21
Interest & Investment Income	5.59	10.32	9.81	11.5	16.4	14.61
Currency Exchange Gain (Loss)	0	0	-0	-	-	-
Other Non Operating Income (Expenses)	4.83	0.27	-0.17	-0.03	-0.03	-0.02
EBT Excluding Unusual Items	72.12	72.95	38.1	94.64	93.11	106.51
Gain (Loss) on Sale of Investments	1.41	1.38	-4.67	-2.61	-1.33	1.21
Gain (Loss) on Sale of Assets	-	-	0.06	-	-0.01	-0.01
Asset Writedown	-0.05	-0.03	-2.37	-0.17	-	-
Other Unusual Items	21.2	19.14	11.68	16.37	11.65	29.34
Pretax Income	94.68	93.44	42.8	108.24	103.42	137.05
Income Tax Expense	17.94	16.71	10.1	9.84	11.64	17.86
Earnings From Continuing Operations	76.73	76.73	32.7	98.4	91.78	119.19
Net Income	76.73	76.73	32.7	98.4	91.78	119.19
Net Income to Common	76.73	76.73	32.7	98.4	91.78	119.19
Net Income Growth	78.66%	134.66%	-66.77%	7.21%	-22.99%	-29.79%
Shares Outstanding (Basic)	418	-	418	403	401	401
Shares Outstanding (Diluted)	418	-	418	403	401	401
Shares Change (YoY)	-0.02%	-	3.60%	0.49%	0.06%	0.21%
EPS (Basic)	0.18	-	0.08	0.24	0.23	0.30
EPS (Diluted)	0.18	-	0.08	0.24	0.23	0.30
EPS Growth	78.69%	-	-67.92%	6.69%	-23.04%	-29.93%
Free Cash Flow	159.82	145.62	126.52	-47.57	26.21	66.95
Free Cash Flow Per Share	0.38	-	0.30	-0.12	0.07	0.17
Dividend Per Share	-	-	0.050	0.070	0.050	0.028
Dividend Growth	-	-	-28.57%	40.00%	78.57%	-36.36%
Gross Margin	56.64%	57.03%	54.82%	59.17%	52.66%	48.00%
Operating Margin	7.85%	8.05%	4.25%	12.43%	11.22%	12.37%
Profit Margin	9.77%	9.90%	4.73%	12.53%	10.85%	13.51%
Free Cash Flow Margin	20.35%	18.79%	18.30%	-6.06%	3.10%	7.59%
EBITDA	147.49	147.38	111.3	172.13	164.7	156.02
EBITDA Margin	18.78%	19.02%	16.09%	21.92%	19.46%	17.68%
D&A For EBITDA	85.79	85.01	81.9	74.54	69.74	46.89
EBIT	61.69	62.36	29.4	97.59	94.95	109.13
EBIT Margin	7.85%	8.05%	4.25%	12.43%	11.22%	12.37%
Effective Tax Rate	18.95%	17.89%	23.59%	9.09%	11.25%	13.03%
Revenue as Reported	785.37	774.82	691.54	785.18	846.14	882.47

Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.